ID   184B5
AC   CVCL_4688
AS   CVCL_B387; CVCL_Y092
SY   184-B5; B5/589; H184B5
DR   BTO; BTO:0002180
DR   CLO; CLO_0001138
DR   ATCC; CRL-8799
DR   BioSample; SAMN03471211
DR   ChEMBL-Cells; CHEMBL4295444
DR   ChEMBL-Targets; CHEMBL4296396
DR   DepMap; ACH-001827
DR   GEO; GSM1172933
DR   GEO; GSM1172845
DR   IZSLER; BS CL 170
DR   LINCS_HMS; 50576
DR   LINCS_LDP; LCL-2081
DR   PharmacoDB; 184B5_5_2019
DR   PubChem_Cell_line; CVCL_4688
DR   Wikidata; Q54582483
RX   DOI=10.1007/978-1-4612-0411-4_10;
RX   DOI=10.1007/978-1-4612-0411-4_26;
RX   Patent=US4808532;
RX   PubMed=2702624;
RX   PubMed=3857588;
RX   PubMed=8504475;
RX   PubMed=9303071;
RX   PubMed=9398663;
RX   PubMed=9671407;
RX   PubMed=24176112;
RX   PubMed=25960936;
RX   PubMed=28196595;
RX   PubMed=28889351;
WW   https://hmec.lbl.gov/mreview.htm
WW   https://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8799.
CC   Doubling time: 56.15 hours (GrayJW panel).
CC   HLA typing: A*02:01,02:01; B*18:01,50:01; C*06:02,07:01; DQB1*06:04,06:04 (PubMed=25960936).
CC   Transformant: ChEBI; CHEBI:29865; Benzo[a]pyrene.
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008359.
ST   Source(s): ATCC; DepMap; IZSLER; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 12,14
ST   D21S11: 29,30
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 11,13
ST   FGA: 19,22
ST   Penta D: 12,13
ST   Penta E: 7,14
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 18,19
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_K049 ! 184
SX   Female
AG   21Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   DOI=10.1007/978-1-4612-0411-4_10;
RA   Yang T.C., Stampfer M.R., Rhim J.S.;
RT   "Neoplastic transformation of human epithelial cells by ionizing
RT   radiation.";
RL   (In) Neoplastic transformation in human cell system. Mechanism of carcinogenesis; Rhim J.S., Dritschilo A. (eds.); pp.103-111; Humana Press; New York (1990).
//
RX   DOI=10.1007/978-1-4612-0411-4_26;
RA   Stampfer M.R., Yaswen P., Parry G., Hosoda J.;
RT   "An in vitro human mammary epithelial model system for studies of
RT   differentiation and carcinogenesis.";
RL   (In) Neoplastic transformation in human cell system. Mechanism of carcinogenesis; Rhim J.S., Dritschilo A. (eds.); pp.259-267; Humana Press; New York (1990).
//
RX   Patent=US4808532;
RA   Stampfer M.R.;
RT   "Continuous human cell lines and method of making same.";
RL   Patent number US4808532, 28-Feb-1989.
//
RX   PubMed=2702624; DOI=10.1016/0165-4608(89)90056-3;
RA   Walen K.H., Stampfer M.R.;
RT   "Chromosome analyses of human mammary epithelial cells at stages of
RT   chemical-induced transformation progression to immortality.";
RL   Cancer Genet. Cytogenet. 37:249-261(1989).
//
RX   PubMed=3857588; DOI=10.1073/pnas.82.8.2394;
RA   Stampfer M.R., Bartley J.C.;
RT   "Induction of transformation and continuous cell lines from normal
RT   human mammary epithelial cells after exposure to benzo[a]pyrene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:2394-2398(1985).
//
RX   PubMed=8504475; DOI=10.1093/carcin/14.5.833;
RA   Lehman T.A., Modali R., Boukamp P., Stanek J., Bennett W.P.,
RA   Welsh J.A., Metcalf R.A., Stampfer M.R., Fusenig N.E., Rogan E.M.,
RA   Harris C.C.;
RT   "p53 mutations in human immortalized epithelial cell lines.";
RL   Carcinogenesis 14:833-839(1993).
//
RX   PubMed=9303071; DOI=10.1002/(SICI)1520-6823(1997)5:3<134::AID-ROI10>3.0.CO;2-6;
RA   Yang T.C.-H., Georgy K.A., Craise L.M., Durante M.;
RT   "Initiation of oncogenic transformation in human mammary epithelial
RT   cells by charged particles.";
RL   Radiat. Oncol. Investig. 5:134-138(1997).
//
RX   PubMed=9398663; DOI=10.1091/mbc.8.12.2391;
RA   Stampfer M.R., Bodnar A.G., Garbe J.C., Wong M., Pan A.,
RA   Villeponteau B., Yaswen P.;
RT   "Gradual phenotypic conversion associated with immortalization of
RT   cultured human mammary epithelial cells.";
RL   Mol. Biol. Cell 8:2391-2405(1997).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//